ArticleEuropean journal of haematology2021
Impact of platelets on major thrombosis in patients with a normal white blood cell count in essential thrombocythemia.
Article in European journal of haematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 16 citations in OpenAlex.
- Immature Platelet Fraction as a Surrogate Marker of Thrombo-Inflammation in Hospitalized COVID-19 Patients.Life (Basel, Switzerland) · 2025Article
- Review
- Real-world characteristics and treatment patterns in essential thrombocythemia: a population-based cross-sectional study in Taiwan between 2020 and 2021.Therapeutic advances in hematology · 2025Article
- Risk factors for thrombotic events in Philadelphia chromosome-negative myeloproliferative neoplasms: a retrospective analysis of 336 cases.Frontiers in oncology · 2025Article
- Perioperative outcomes in patients with myeloproliferative neoplasms: a multicentric analysis of 354 surgical procedures.Blood vessels, thrombosis & hemostasis · 2024Article
- Brevianamide F Exerts Antithrombotic Effects by Modulating the MAPK Signaling Pathway and Coagulation Cascade.Marine drugs · 2024Article
- Prediction of acute coronary syndrome in patients with myeloproliferative neoplasms.Frontiers in cardiovascular medicine · 2024Article
- Application of IPSET-thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia.HemaSphere · 2023Article
- Impact of platelets on major thrombosis in patients with a normal white blood cell count in essential thrombocythemia.European journal of haematology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesCell counts have a significant impact on the complex mechanism of thrombosis in patients with essential thrombocythemia (ET). We recently demonstrated a considerable impact of white blood cell (WBC) counts on thrombotic risk in patients with optimized platelet counts by analysing a large anagrelide registry. In contrast, the current analysis of the registry aimed to estimate the influence of platelet counts on thrombotic risk in patients with optimized WBC counts.
methodsCox regression analysis and Kaplan-Meier plot were applied on all patients in the registry with optimized WBC counts.
resultsBy using the calculated cut-off of 593 G/L for platelets, Cox regression analysis revealed a clear influence of elevated platelet counts on the occurrence of a major thrombotic event (P < .001). A Kaplan-Meier plot revealed a markedly shorter time to a major thrombotic event for patients with platelet counts above the cut-off (P < .001).
conclusionsThe data show clear impact of platelet lowering on the thrombotic risk in ET patients with normal WBC counts. Therefore, selective platelet lowering with anagrelide appears sufficient for thrombotic risk reduction in WHO-diagnosed ET patients lacking leukocytosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.